Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
about
Systemic delivery to central nervous system by engineered PLGA nanoparticlesNanocarriers for diagnosis and targeting of breast cancerNanoscopic imaging of thick heterogeneous soft-matter structures in aqueous solution.Stealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersFormulations for trans-tympanic antibiotic delivery.Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions.Real-time intravital microscopy of individual nanoparticle dynamics in liver and tumors of live miceA Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment.Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength.Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice.Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations.Poloxamer 188 facilitates the repair of alveolus resident cells in ventilator-injured lungs.Targeted imaging and therapy of brain cancer using theranostic nanoparticlesTransport of biological molecules in surfactant-alginate composite hydrogels.Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.Nanotechnology for targeted cancer therapy.Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.Agents under investigation for the treatment and prevention of neutropenia.Factors affecting the clearance and biodistribution of polymeric nanoparticles.Role of nanocarrier systems in cancer nanotherapy.Standardization of models and methods used to assess nanoparticles in cardiovascular applications.Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitro.Preparation of Thermosensitive Gel for Controlled Release of Levofloxacin and Their Application in the Treatment of Multidrug-Resistant Bacteria.An In Situ Gelling Drug Delivery System for Improved Recovery after Spinal Cord Injury.Evaluation of a PSMA-targeted BNF nanoparticle construct.Development of small scale cell culture models for screening poloxamer 188 lot-to-lot variation.Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies.Facile Synthesis of PEGylated PLGA Nanoparticles Encapsulating Doxorubicin and its In Vitro Evaluation as Potent Drug Delivery Vehicle.In vivo retention of poloxamer-based in situ hydrogels for vaginal application in mouse and rat models.Effect of polyoxyethylene and polyoxypropylene nonionic block copolymers on performance and recruitment of immune cell subsets in weaned pigs.Effect of PEG surface conformation on anticancer activity and blood circulation of nanoemulsions loaded with tocotrienol-rich fraction of palm oil.A novel transdermal honokiol formulation based on Pluronic F127 copolymer.Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models.Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain.Release of ciprofloxacin from chondroitin 6-sulfate-graft-poloxamer hydrogel in vitro for ophthalmic drug delivery.Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury.Formulation of Poloxamers for Drug Delivery.Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases.
P2860
Q26751294-C5C7F988-F0AC-4D77-82DA-F6F2C427D011Q26862309-A9112865-8038-488F-B72B-257B210EA197Q27327654-D7819EE0-21FA-4069-88D1-39FA3823F233Q27496024-8C43B67C-C589-4B1F-A83A-286A9CFDE6D6Q30444996-B7655732-C43B-4836-82D8-B6026ADF4788Q30472664-50855539-0808-453D-A1D3-C23F051D373EQ30596892-1CA62E9C-093F-4259-99BD-B42223382B5DQ33949801-7E23DDDB-F4F0-4042-B92E-36E389A9453CQ34025399-20680F42-9DBC-4A8B-AE99-FAC64AE37F4AQ34183401-B2D5D551-AD04-4BBF-B8A5-0BC9CB2C27EFQ34312430-B2577108-5249-4BC1-945F-432037B1EB36Q35528482-C58DCA86-E952-462D-B0B8-E71CAAC3EA77Q35792897-72FB6727-2998-4944-AA5D-F61E449329AEQ36585009-F27BEAEF-2E36-4F1C-974F-2A6AE023B94CQ36591050-B13E9DFA-C1B6-47BD-9A0E-9DEF53F0010DQ36842770-ED85F7AA-05FE-4A0E-91A4-0A04ABC3E458Q36933043-A0CBE46C-3EA3-4058-89C4-3A64C7F0E658Q36985881-8232A22A-C83B-4A05-93E0-FF09BCCE7EC2Q37146591-726A9541-225E-456B-A3A9-08F9AE9B957BQ37622867-B34B9C99-4DD0-4AB7-AAD9-6EF92ECC350CQ37841416-C7B5D64D-A3DD-4D2F-B293-2C0B971D4C2AQ38289271-57FAFABD-2C1C-4A6B-A59E-C8FBA9E17904Q38787429-24A316BC-8395-45B5-A617-6835CF393051Q38816087-8C397461-B065-4AB0-97D3-5FF6479078ACQ38876101-A0FBEA92-B3DB-4C44-851D-133DC48F8EA0Q38910401-826696DE-671D-4836-8B99-B9436BF445C6Q38968289-1C284675-977D-4E8A-A973-4BAEC15C780EQ38993209-61DF8CB2-36B7-4A48-AEF2-75A0B3044FF6Q39115464-18F7CD0E-43C5-495E-AD36-FDE7CF78B265Q41068671-F826F55D-32AB-4DE5-AC01-84E37ADAC918Q41980795-CD3E6893-2D6F-4BFF-AE5C-3940E02A6766Q42122956-8EBECE99-C6FF-461E-AB97-16C32644C822Q43154126-0C2F6E65-29B5-4495-ACBE-0F6703246F09Q45873535-540D09E8-E97E-4584-86CF-90E71C4E7E29Q46489252-9B9424E5-EFB6-4A0C-A3C6-58DFAAD6F5A9Q46644189-01A6EDC9-1249-4929-91FE-196251DA9F75Q46811202-DEC6D6D7-3EB8-47A2-912C-0257E75086D2Q47422073-6D19A8A2-D6A7-4C08-81E0-D053B075EDF2Q47711535-622EF9A8-522F-48B7-A4CF-D963576EA993Q47975293-A7369F80-2325-48ED-9B5A-24836A80EC21
P2860
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@ast
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@en
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@nl
type
label
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@ast
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@en
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@nl
prefLabel
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@ast
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@en
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.
@nl
P1476
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine
@en
P2093
P304
P356
10.1016/S0167-7799(00)01485-2
P577
2000-10-01T00:00:00Z